| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910972 | Lung Cancer | 2015 | 7 Pages |
Abstract
Our study failed to demonstrate significant PFS improvement with the docetaxel-platinum doublet compared to single-agent docetaxel. The 3.6-month improvement in OS with the cisplatin-based doublet proves, however, appealing and merits further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, Elisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlesi, Christos Chouaid, Olivier Molinier, Jaafar Bennouna, Armelle Lavolé, Julien Mazières, Anne-Claire Toffart, Alexandra Langlais,